Previous 10 | Next 10 |
MiMedx Group is in the early stages of a sales recovery, after a turbulent last 2 years. 90% of management are new faces, and the new growth strategy dovetails to include commercialization, R&D focus and supply chain integration. Their amniotic hypotheses have high commercial ...
MARIETTA, Ga., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today provided additional information about its upcoming virtual 2020 An...
MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, ...
MiMedx Group, Inc. (MDXG) Q3 2020 Earnings Conference Call November 05, 2020, 08:30 AM ET Company Participants Hilary Dixon - VP of IR and Corporate Communications Tim Wright - Chief Executive Officer Pete Carlson - Chief Financial Officer Bob Stein - Executive VP, Research & Development ...
MiMedx Group (MDXG): Q3 GAAP EPS of -$0.48.Revenue of $64.3M (-27.6% Y/Y)Non-GAAP Revenue of $63.26M (-6.3% Y/Y).Press Release For further details see: MiMedx Group reports Q3 results
Third Quarter Net Sales of $64 . 3 M illion , Above Preliminary Range Common S tock Relisted on The Nasdaq Stock Market U nder t he T icker S ymbol “MDXG” Company to Host Conference ...
Company to Showcase Newly Launched EpiCord Expandable Product Line MARIETTA, Ga., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics compan...
MiMedx (MDXG) to commence trading on Nasdaq on November 4, 2020, under the ticker symbol “MDXG”. Source: Press Release For further details see: MiMedx to commence trading on Nasdaq on November 4
MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today confirmed that the Company’s common stock will commence t...
MiMedx Group (MDXG) announces that the largest U.S. commercial payor will cover its EpiFix tissue product for the treatment of diabetic foot ulcers effective December 1.Beleaguered longs are hoping the news lifts the stock considering its 20% drop this year. For further details se...
News, Short Squeeze, Breakout and More Instantly...
Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDX’s first publication in the 5 th most-cited journal in the world MARIET...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 3...